Terug

Crucell N.V.

Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.

  • Publicatie datum 22 dec 2006 - 08:03
  • Statutaire naam Crucell N.V.
  • Titel Crucell subsidiary awarded EU grant to develop malaria vaccine
  • Bericht Crucell subsidiary awarded EU grant to develop malaria vaccine Leiden, The Netherlands, December 22, 2006 – Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) today said the European Union had awarded a grant to its subsidiary toward the development of a Malaria vaccine. The €1.7 grant was given to a consortium of four leading groups in the field of Malaria research including Etna Biotech, a fully-owned Crucell group company. Etna Biotech is based in Catania, Italy. The Malaria vaccine will be based on Crucell’s Recombinant Paramyxovirus technology. “We are very delighted by the EU’s decision to offer this grant as it further demonstrates the importance for Recombinant Paramyxovirus technology toward the development of a malaria vaccine,” said Reinhard Glueck Etna Biotech’s CEO. “The EU grant is by no doubt an important step toward the development of a much-needed vaccine.”

Datum laatste update: 21 januari 2020

Informatie delen

Delen via: deel